We firstly analyzed the association of TMEM211 expression with clinicopathological outcomes, and found that the expression level of TMEM211 was not significantly different between female/male or young (≤70 y)/old (>70 y), having an early (I + II)/late (III + IV) pathological stage, having a small (T1 + T2)/large (T3 + T4) tumor size and having no (N0)/high risk (N1 + N2) lymph node metastasis in colon cancer patients (Table S2). This evidence concerns the gene LHFPL7 and metastatic malignant neoplasm in the lymph nodes.